MNOV vs. ACB, AQST, CMPX, DBVT, CRVS, IMMP, RNAC, AURA, CGC, and TSVT
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), Canopy Growth (CGC), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry.
MediciNova vs.
MediciNova (NASDAQ:MNOV) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.
MediciNova has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.
Aurora Cannabis received 171 more outperform votes than MediciNova when rated by MarketBeat users. Likewise, 59.63% of users gave Aurora Cannabis an outperform vote while only 47.02% of users gave MediciNova an outperform vote.
In the previous week, MediciNova and MediciNova both had 1 articles in the media. Aurora Cannabis' average media sentiment score of 0.81 beat MediciNova's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.
MediciNova currently has a consensus target price of $9.00, suggesting a potential upside of 547.48%. Given MediciNova's higher possible upside, equities analysts plainly believe MediciNova is more favorable than Aurora Cannabis.
9.9% of MediciNova shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 14.9% of MediciNova shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Aurora Cannabis has a net margin of 0.42% compared to MediciNova's net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat MediciNova's return on equity.
MediciNova has higher earnings, but lower revenue than Aurora Cannabis. MediciNova is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Summary
Aurora Cannabis beats MediciNova on 13 of the 17 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
This page (NASDAQ:MNOV) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy MNOV Stock Free MNOV Stock Alerts